meg tirrell has a closer group banding together to tackle the crisis >>> while covid-19 takes an everr toll on mortality, heart disease is still the country's number one killer. boy tech company verve therapeutics -- >> to treat heart attack, so really think a one and done for cardiovascular disease, permanent lowering of cholesterol. to do that work, verve's employees has been to be in the labs covid-19 makes that complicated. >> our work involves work in cells and animal models, the kind of work can't do at home. >> with an many at 30%, verve's ceo knew that surveillance testing, about you it wasn't immediately clear how to access that testsing. got together with a cup the ceo, and we developed the infrastructure the green partnered with the broad institution in cambridge, massachusetts. that's one of the largest genome research centers in the world. >> we ran from around 1,000 tests a day to 10,000, and right now we have the instrumentation in place for around 35,000 tests per day. >> it also engaged color, a bay hear health technology company to operate and streamline the testing

is unique >> yes, i have yet to see anything where it's not precedent setting, that's for sure meg tirrell, thank you >> thanks. >>> roku racks up revisewreview, more when "the exchange" comes back >>> it is time to catch you up on a few of the stories that should be on your radar. it is time for "rapid fire" and here with their takes on these stories, mike santoli, deirdre bosa and one robert frank. good to see you all. the streaming player roku higher after being a buy, they got a 50% market share in the so-called connected tv market as well as growth potential in the u.s., ad revenue as major tailwinds exist for that company. it comes as roku logged nearly 15 billion hours worth of content that was streamed on its platform in the second quarter of course, the stay-at-home trade in full effect here. talk about being in the right place at the right time, dee >> right place at the right time, but i was surprised, bill, the stock is only up 12% year to date perhaps it is an opportunity that's certainly what deutsche bank believes. what's interesting about this company, when it went public a

. ♪ >>> welcome back ie lay eli lilly with word they're going to start antibody trials meg tirrell is meg? >> hi, kelly this is an important trial given the severity of the disease and the more deaths that we see in the nursing home in older populations. lilly is running this trial in partnership with the national institute of allergy and infectious diseases to see if they can use this antibody drug as a preventive in settings that have had a case of covid-19, actually going in to try to protect residents and staff at these facilities what this drug is is an antibody that was actually derived from one of the first u.s. survivors of covid-19, and they're testing it both as a prevention and a potential treatment. of course, they're not the only company in this race regeneron also started late stage clinical trials last month. so joining us now to tell us more about this trial and this approach in general the lilly's chief sign particular officer dr. daniel skovronsky. thank you for being with us today, and i want to ask you about this specific trial, but tell us first about the trials y

meg, thank you meg tirrell with the latest information. >>> still ahead, a news platform launching todayrs to gain access to the liquidity we'll delk talk to the ceo nextn "the exchange. >>> welcome back investors with alternatives assets are often left frustrated when they can't get liquidity during market volatility now a company is helping investors tap that money for more on what this could mean in practice, i'm joined by brad heppner. welcome, brad. >> thank you, kelly. appreciate your time here today. >> how did this change the options for people who need access to the money and usually can't get it right away. >> the objective we have is to provide it raptly for individuals. we've been built for individuals. that's the growing segment of investorses in alternates tiff assets today. >> what is the cut that you guys would take in order for me to -- let's say a life insurance policy or invested in private equity, something like that. i want that money. are you kind of fronting it for me taking the cut we deal -- how did is it work. >> think of us more like a bank. we operate on a spr

for that meg tirrell joins us with more. meg? >> reporter: hey, brian.moving into clinical trials designed specifically for covid-19 from glax so smi glaxosmithkline. an antibody drug that fights the coronavirus and this one actually fights both sars co-v 1 and 2 and using to try to be prevent hospitalization due to covid-19 so they dosed the first patient in the trial which they call a phase ii iii, usually means later phase in studies this is actually the first in human test as well starting a safety trial in about 20 patients, participants, in the united states. and if all looks good, they're going to extend that to as many as 1,300 people toal see if this andy body drug can prevent severe disease in covid-19 early cases. followed eli lilly testing their drug in treatment and kpreechprn of the disease could have initial data by end of the year. if it, woulds, potentially could be available soon as first half of next year a lot of shots on goal here, because even if they all work, the supply might be constrained at the beginning watching these closely

weturn to meg tirrell. hi, meg. >> reporter: hi, scott this drug advancing through clinical trials.udy being started by eli lilly with an antibody drug for covid-19 it's a prevention trial where they're targeting places like nursing homes that have had outbreaks. this is in partnership with the national institute of allergy and infectious diseases and aims to see if they can use the drug to prevent infection in the high-risk settings what it is, it's an antibody derived from one of the first u.s. patients to recover from covid-19 it's designed to treat and prevent the disease. early stage results show that it is safe. we do not yet have data on its efficacy what's really interesting about the trial is how they're running it they're going to enroll up to 2400 residents and staff at these nursing homes that have had a case of covid-19 they're going to deploy a mobile fleet of rvs and trailer trucks to prevent more cases in nursing homes that have already had one. here lilly is joining regeneron to try to prevent disease. they're testing them for treatment so moving pretty quickly alon

mark bristol on, is that how it works oh, cnbc -- why don't we go to meg tirrell, david >> yeah, let'set to meg for more on russia's claims for having a covid vaccine meg, fill us in. >> hi, david, we should make really clear that russia has said it's approved this vaccine, not because it's broad tell through broad-scale testing to ensure that it is actually protective against the coronavirus and that it's broadly safe, but because they decided to approve it after only initial small trials in a few dozen people and after animal studies to make the comparison, we are that far along with multiple vaccines here in the united states with companies like moderna and pfizer and the uk with astrazeneca and auctioxd and russia does plan a long-term trial but we don't know the safety of the vaccine. i was talked to paul offit saying there is no way them should have evidence that this vaccine works to this point. it's two other viruses called adeno-viruses used to ferry the genetic material these are programs used with johnson & johnson. know companies are combining and this is different in that

. >> meg tirrell, thank you. >>> meanwhile, we're waiting policy decisions out of washington how would a new stimulus package and potential capital gains tax cut impact the market? let's bring in chris krueger he joins us by phone interesting, chris that, the president did float the idea of cutting capital gains. he can't do that unilaterally, can he what are the options here? >> well, i mean, we're pretty short on details and long on aspirations. we're assuming this is the idea that's been around since the george h.w. bush administration which would undechl capital gains to inflation to be clear, was a lot of the executive orders, we're really -- it's mainly foam and very little beer it's not like a magic wand you wave and you have economic stimulus when we look at the way the stock market rebounded and the economy has not in the sort of imbalance there. not to mention the fact that government debt levels have soared and have to be paid for one way or another, can you make quite a clear case for why certain taxes particularly capital gains on stocks, for example, should be going up. d

but while some states have a long turnaround time others have excess testing capacity right now meg tirrelloins us to break that down. >> mike, so we hear stories about people who have to wait more than a week or two weeks or three weeks to get their covid test results back, but we also hear stories about states that may have excess capacity it turns out state health departments don't uniformly report this information. we partnered with survey and data company dinata to do a survey of americans about their testing experience they surveyed more than 9,400 americans in 50 states and found that about 60% of people reported getting their results in less than three days. that is really the cutoff that experts like harvard tells us is the cut-off for utilities of the results. that means 40% of americans are getting more slowly than that making them not useful if you look at the state by state breakdown the differences are stark. some states people are reporting getting their test results on average of just more than two days, states like south dakota and massachusetts, but other states are seeing

of doses of a vaccine if and when it does get through phase three trials into i was listening to meg tirrellhis morning and i was looking at an email how much is regeneron getting. $500 million in july i would say, david, is there any amount that you wouldn't spend on these companies to get this thing beaten because if we're spending $2 trillion to just try to stay in place we have got to flood the market with money. make it so it's worth wise for everybody. i have emerging bio tonight, they would be helping making a lot of these giant doses and i don't think -- i think that you have to encourage these companies. it is really important, novavax getting a lot of money i want to see j & j and pfizer get the money but they have to do it, david they have to >> and they all will i think this he all will operation warped speed which is the name that the administration has given to trying to develop a vaccine and anti-virals and therapeutics as quickly as possible, there's money for all of them in terms of manufacturing and the department of defense has contacted many of them they are choosing in s

moderna latest for a deal in operation warp speed meg tirrell has the deal. >> this is the sixth deal for the government to supply covid-19 vaccines if they are successful getting through testing. they will be paying more than $1.5 billion to secure more than 100 million doses. putting a price tag on these vaccines of $15.25 per dose. this is how this lines up with the other deals that the government has struck. now, some of these numbers are going to be different like astrazeneca and novavax which include support for development. johnson & johnson, the most recent company before moderna to strike a deal for a billion dollars for 100 million doses, about $10. while moderna is on the higher end, pfizer the highest, it took no government funding for development it's lower than the price moderna had been telegraphing for vaccines. you see their stock with gains on that news. >> meg, what is operation warp speed. who makes these decisions and how is the government picking winners and losers, especially when it goes to backing not just vaccines but they say they are going to back treatment